What drives the success of leading pharmaceutical companies like Pfizer Johnson & Johnson, and Merck ? Regeneron Pharmaceuticals, with over 10,000 employees, focuses on immuno-oncology, leveraging its VelociSuite technology platform. Similarly, Gilead Sciences, led by its innovations in antiviral treatments, employs over 17,000 people globally. #Pharmaceuticals #Biotech
Healthcare Digital’s Post
More Relevant Posts
-
The global pharmaceutical market is 1475 billion USD in 2022 growing at a CAGR of 5% during the next six years. In comparison the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U. S. dollars in 2022. #GlobalPrecisionCancerDiagnostics #CancerCare #EarlyDetection #PersonalizedMedicine #AdvancedDiagnostics #HealthcareInnovation #OncologyResearch #PatientOutcomes #MedicalTechnology #CancerTreatment
Global Precision Cancer Diagnostic Solutions Market Research Report 2024
reports.valuates.com
To view or add a comment, sign in
-
🚀 Exciting news from Celltrion! 🚀 Celltrion Inc has successfully secured bids to supply three key biopharmaceutical products #Remsima (infliximab), #Herzuma (trastuzumab), and #Vegzelma (bevacizumab) to UniHA, France's largest pharmaceutical procurement group. These biosimilars treat #autoimmunediseases, #breastandgastriccancer, #colorectalcancer, and #nonsmallcelllungcancer. #UniHA controls significant market shares: 30% infliximab, 27% bevacizumab, and 13% trastuzumab. As a result, Celltrion will be the exclusive supplier of these products until June 2027. Additionally, through the #Bretagneprocurementgroup, Celltrion will supply #Herzuma and #Vegzelma until June 2028. Celltrion’s strategy focused on strong relationships with key stakeholders, ESG achievements, and supply stability. The company's #RemsimaSC has also captured a 26% market share, contributing to a combined 76% share for the #Remsima line in France. Looking ahead, Celltrion plans to expand its participation in the French bidding market and strengthen its sales capabilities for newly approved products like #Omviclone (omalizumab) and #CT-P43 (ustekinumab). The company will aggressively participate in upcoming bids and strive for outstanding results to ensure more patients benefit from Celltrion's treatments. #Celltrion #Pharmaceuticals #Biosimilars #Healthcare #Innovation #France #UniHA #Bretagne #Remsima #Herzuma #Vegzelma #Omviclone #CTP43 #Infliximab #Trastuzumab #Bevacizumab #Omalizumab #Ustekinumab #RASLifeScienceSolutions #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization #MarketExpansion #PartnerIdentification For Detailed News: https://lnkd.in/d94c3p4T Follow our page for more industry updates: https://lnkd.in/de5zNWmK
Celltrion secures supply contracts for 3 biosimilars in France
koreabiomed.com
To view or add a comment, sign in
-
Director @ RAS LifeScience Solutions | Business Development | Competitive Intelligence | Market Intelligence | Market Entry Strategy Expert | Pharmaceuticals/Biotech/Healthcare
#Celltrion secures major supply contracts with #UniHA and #Bretagne, strengthening market leadership in France #Celltrion #Pharmaceuticals #Biosimilars #Healthcare #Innovation #France #UniHA #Bretagne #Remsima #Herzuma #Vegzelma #Omviclone #CTP43 #RASLifeScienceSolutions #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization #MarketExpansion #PartnerIdentification
🚀 Exciting news from Celltrion! 🚀 Celltrion Inc has successfully secured bids to supply three key biopharmaceutical products #Remsima (infliximab), #Herzuma (trastuzumab), and #Vegzelma (bevacizumab) to UniHA, France's largest pharmaceutical procurement group. These biosimilars treat #autoimmunediseases, #breastandgastriccancer, #colorectalcancer, and #nonsmallcelllungcancer. #UniHA controls significant market shares: 30% infliximab, 27% bevacizumab, and 13% trastuzumab. As a result, Celltrion will be the exclusive supplier of these products until June 2027. Additionally, through the #Bretagneprocurementgroup, Celltrion will supply #Herzuma and #Vegzelma until June 2028. Celltrion’s strategy focused on strong relationships with key stakeholders, ESG achievements, and supply stability. The company's #RemsimaSC has also captured a 26% market share, contributing to a combined 76% share for the #Remsima line in France. Looking ahead, Celltrion plans to expand its participation in the French bidding market and strengthen its sales capabilities for newly approved products like #Omviclone (omalizumab) and #CT-P43 (ustekinumab). The company will aggressively participate in upcoming bids and strive for outstanding results to ensure more patients benefit from Celltrion's treatments. #Celltrion #Pharmaceuticals #Biosimilars #Healthcare #Innovation #France #UniHA #Bretagne #Remsima #Herzuma #Vegzelma #Omviclone #CTP43 #Infliximab #Trastuzumab #Bevacizumab #Omalizumab #Ustekinumab #RASLifeScienceSolutions #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization #MarketExpansion #PartnerIdentification For Detailed News: https://lnkd.in/d94c3p4T Follow our page for more industry updates: https://lnkd.in/de5zNWmK
Celltrion secures supply contracts for 3 biosimilars in France
koreabiomed.com
To view or add a comment, sign in
-
Regulatory Affairs Professional || Regulatory Compliance || Regulatory Strategy || CAPA || Change control || Pre-clinical and Clinical Research || Actively seeking full time opportunities in Regulatory and Quality domain
📢Exciting News 📍 Today, Accord Biopharma, Inc. a subsidiary of Intas Pharmaceutical Ltd has gotten the acceptance of its #Biosimilar DMB-3115 which is proposed biosimilar to STELARA ® (ustekinumab) from #USFDA 📌Accord Biopharma, Inc. conducted multi-regional Phase-III clinical trail in patients with plaque psoriasis. The main focus of the study was the rate of change in the Psoriasis Area and Severity Index (PASI) to assess skin symptom improvement. 💊 STELARA®, a Janssen Biotech blockbuster, approved for psoriasis, psoriatic arthritis, Crohn's, and colitis. It raked in $13.9B in U.S. sales in 2022, ranking among top biologics. #Biosimilar #USFDA #ustekinumab #accordbiopharma #Intas https://lnkd.in/eQiVMPst
Accord BioPharma, Inc. Announces U.S. FDA Acceptance of Biologics License Application for Proposed STELARA® Biosimilar DMB-3115
prnewswire.com
To view or add a comment, sign in
-
Hi. It's getting very hot in Japan. We've posted a new blog article regarding the sales highlight of Japan's drug market in 2023 as follows: https://lnkd.in/gpFYRYDc We are a part of ELIQUENT Life Sciences that creates an unprecedented assembly of global regulatory leaders, industry experts, and technical specialists - brought together to bridge the spectrum of regulatory challenges across the product lifecycle. The collective capabilities of the united ELIQUENT team enable a comprehensive approach that delivers integrated solutions to support pharmaceutical, biotechnology, medical device, and combination product companies navigating the complex global regulatory landscape. Top Performing Products: Keytruda (Pembrolizumab) reclaimed the top sales position, surpassing Opdivo (Nivolumab), which experienced a 4.2% revenue decline in Q1 2024 due to a 15% price cut in April. Oncology Market Dominance: The oncology market grew by 9.8% to nearly 2 trillion yen, representing 17% of the domestic market. Keytruda led with a 22.5% increase to 164.8 billion yen. Opdivo grew by 3.5% to 164.5 billion yen but fell to second place due to market recalculation impacts. Imfinzi (Durvalumab) posted a 116% growth, reaching 120.7 billion yen, following new cancer indications. Significant Growth in the Following Therapeutic Areas.......
Record-Breaking Growth in Japan’s Pharmaceutical Market for FY2023
https://idec-inc.com/blog
To view or add a comment, sign in
-
KORU today announced a collaboration with a global pharmaceutical company to initiate a feasibility study with the Freedom System for an FDA and EMA approved subcutaneous oncology biologic drug currently being delivered via manual syringe administration by healthcare professionals. The Freedom System is a purely mechanical ambulatory drug delivery device with 11 drugs approved on the label and over 40,000 patients globally. It’s designed to deliver large volumes of biologic medications subcutaneously and is capable of allowing patients to self-administer at home or by healthcare professionals in a clinic setting. Conversion of intravenous biologics to subcutaneous administration formulations is a growing trend in the oncology market. Evidence suggests subcutaneous administration of oncology therapy simplifies treatment, reduces pressure on hospitals, and improves quality of life. With the development of new subcutaneous drug therapies, there is an opportunity to develop drug delivery administration solutions which will optimize drug administration. “This collaboration presents an exciting, new opportunity to enter the growing oncology subcutaneous biologic market to solve significant unmet needs in the delivery of this life-saving therapy with our patient-centric solutions,” said Linda Tharby, KORU Medical’s President and CEO. “There are multiple subcutaneous oncology biologics currently approved using manual administration with an estimate of over one million global infusions. We anticipate progressing to commercialization of the Freedom System for this drug within 12 months.” Read full announcement here: https://hubs.la/Q02zL76s0 #KORU #FreedomInfusionSystem #FreedomInfusion #Milestone
To view or add a comment, sign in
-
Exciting strides in the pharmaceutical world! Sally Turner’s recent article for Pharmaceutical-Technology explored the most groundbreaking pharmaceutical breakthroughs of 2023 with the valuable insights from Surbhi Gupta, Senior Industry Analyst, Growth Opportunity Analytics – HLS, at Frost & Sullivan. 🌐 From cancer treatments to rare diseases, the pharmaceutical industry is revolutionizing healthcare. Explore the top 10 novel drugs that made headlines. #MedicalAdvancements #PharmaBreakthroughs
Pharma breakthroughs: 10 novel drug approvals that made headlines in 2023 - Pharmaceutical Technology
pharmaceutical-technology.com
To view or add a comment, sign in
-
Did you know? 80% of the top 10 Pharmaceutical companies are increasing their orphan drug portfolios over the next 3 years towards 35% on average for their respective drug portfolios? With Johnson and Johnson (39%), Vertex (98%), and Astrazeneca (36%) leading the way according to the Evaluate industry report. The ESN Cleer Team 🫀 #capitalcell #cleerhealth #therapeuticscompany #heartfailure #developing #cardiovasculardisease #heartdisease #hearthealth #heartattacks #heart #stroke #blood #diagnosticstreatments #personalisedmedicine #BiotechInvestment #PharmaPartnerships #OrphanDrug #CardiomyopathyResearch #HealthInnovation #BioTechDevelopment https://lnkd.in/gJbZjvZa
Evaluate Orphan Drug Report.pdf
info.evaluate.com
To view or add a comment, sign in
-
Recruitment Consultant - Quality & GMP Manufacturing within the Pharmaceutical and Biotechnology sector
Great article detailing the top 20 drugs worldwide by sale in 2023: The predominance of monoclonal antibodies (mAbs) among the top 20 drugs by sales in 2023 is extremely clear and can be attributed to several key factors: 1. **Targeted Therapy**: Monoclonal antibodies are highly specific to their targets, which allows them to effectively target and neutralize disease-causing agents, particularly in cancer and autoimmune diseases. This specificity results in better efficacy and fewer off-target effects compared to traditional small-molecule drugs. 2. **Advancements in Biotechnology**: Over the past few decades, significant advancements in biotechnology have enabled the efficient production and development of monoclonal antibodies. Techniques like recombinant DNA technology and hybridoma technology have streamlined the creation of these complex biologics. 3. **High Unmet Medical Needs**: Many mAbs address conditions with high unmet medical needs, such as various forms of cancer, rheumatoid arthritis, and other autoimmune diseases. Diseases in these categories often have fewer effective treatment options, and mAbs can offer significant therapeutic benefits. 4. **Market Exclusivity and Patent Protection**: Monoclonal antibodies often benefit from extended market exclusivity and strong patent protection, allowing pharmaceutical companies to maintain higher prices for longer periods. This exclusivity can make mAbs highly profitable. 5. **Clinical Efficacy and Safety**: Monoclonal antibodies have shown impressive clinical efficacy and safety profiles in treating a range of serious conditions. Their ability to specifically target disease mechanisms often results in better outcomes and fewer side effects, enhancing their adoption in clinical practice. 6. **Chronic Diseases and Long-Term Use**: Many mAbs are used to treat chronic conditions that require long-term management. This leads to sustained demand and consistent sales over time, contributing to their high sales volumes. 7. **Regulatory Approvals and Expanding Indications**: Regulatory bodies have approved numerous monoclonal antibodies for a wide range of indications. Furthermore, many mAbs receive additional approvals for new indications beyond their original use, expanding their market and sales potential. 8. **Strong Commercialization and Marketing**: Pharmaceutical companies have heavily invested in the commercialization and marketing of monoclonal antibodies. This includes educational campaigns for healthcare providers and patients, which increase awareness and adoption of these therapies. In summary, the top sales rankings of monoclonal antibodies in 2023 are driven by their targeted action, clinical effectiveness, ability to meet significant medical needs, strong patent protection, and successful commercialization efforts. full article: https://lnkd.in/eQx636x4 #biotechnology #pharmasales #qualityassurance
The top 20 drugs by worldwide sales in 2023
fiercepharma.com
To view or add a comment, sign in
-
The global pharmaceutical market is 1475 billion USD in 2022 growing at a CAGR of 5% during the next six years. In comparison the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U. S. dollars in 2022. #GlobalOncology #MolecularDiagnostics #CancerResearch #BreastCancer #ProstateCancer #ColorectalCancer #CervicalCancer #PCR #MultiplexPCR #InSituHybridization
Global Oncology Based Molecular Diagnostics Market Research Report 2024
reports.valuates.com
To view or add a comment, sign in
7,007 followers
More from this author
-
Healthcare Monthly Digest: Unveiling Innovations and Leaders Shaping the Future of Healthcare
Healthcare Digital 3mo -
Fostering Transgender Inclusivity: A Holistic Approach in the Workplace and Healthcare
Healthcare Digital 9mo -
Women's Health: Breaking Barriers and Building Bridges
Healthcare Digital 10mo